| Dimerix Limited (ASX: DXB), is pleased to announce that a detailed analysis of the data from the DMX-200 Phase 2a clinical trial in Chronic Kidney Disease will be announced to the ASX coincident with its feature as a poster presentation at the American Society of Nephrology (ASN) Kidney Week 2017, to be held in New Orleans, Louisiana from October 31 to November 5, 2017. Associate Professor David Packham, a principal investigator on the DMX-200 clinical trial said, “We are very pleased to be able to present data from the DMX-200 clinical trial at the ASN Kidney Week Meeting. This meeting is known as the world’s pre-eminent gathering of clinical and scientific professionals who are working on developing kidney disease treatments.” Kathy Harrison, Dimerix CEO said: “The ASN’s annual Kidney Week is typically attended by more than 13,000 international kidney specialists and Dimerix has been allocated a poster presentation slot in the clinical trials section of the first session of the conference. It is an exciting opportunity for us to expand upon recently announced top line results of our DMX-200 Phase 2a clinical trial in Chronic Kidney Disease within this world leading forum.” About the poster presentation Those attending the ASN’s annual Kidney Week can view Dimerix’s poster using the details below. Session Title: 305-PO01 CKD: Clinical Trials and Tubulointerstitial Disorders Session Date, Time: November 2, 2017 from 10:00 AM to 12:00 PM Your Poster Board #: TH-PO501 Poster Title: A Phase 2a trial of DMX-200: synergistic blockade of AT1R and CCR2 in patients with Chronic Kidney Disease (CKD) For more information see www.dimerix.com |
